Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermediate effect markers for colorectal cancer.

J A Baron1

  • 1Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03767, USA.

IARC Scientific Publications
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.

The British journal of dermatology·2018
Same author

The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark.

Alimentary pharmacology & therapeutics·2015
Same author

Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer.

British journal of cancer·2014
Same author

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Lancet (London, England)·2013
Same author

KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.

British journal of cancer·2013

Adenomatous polyps serve as valid biomarkers and endpoints in cancer research, mirroring invasive cancer epidemiology. Aberrant crypt foci and ras mutations in stool show promise for chemoprevention trials, despite some limitations.

Area of Science:

  • Gastroenterology
  • Oncology
  • Preventive Medicine

Background:

  • Adenomatous polyps are recognized as biomarkers of risk and surrogate endpoints in colorectal cancer research.
  • The epidemiology of adenomas closely resembles that of invasive colorectal cancer.
  • Findings from completed chemoprevention trials align with this epidemiological similarity.

Purpose of the Study:

  • To evaluate the validity of adenomatous polyps as endpoints in chemoprevention studies.
  • To assess the potential of aberrant crypt foci and ras mutations as biomarkers and endpoints.
  • To examine the utility of mucosal proliferation as a biomarker and endpoint for colorectal neoplasia.

Main Methods:

  • Observational epidemiology of adenomas.
  • Analysis of findings from completed chemoprevention trials.

Related Experiment Videos

  • Evaluation of aberrant crypt foci as biomarkers.
  • Assessment of ras mutations in stool samples.
  • Measurement of mucosal proliferation.

    • Main Results:

    • Adenomatous polyps appear to be valid endpoints due to consistent epidemiological findings.
    • Aberrant crypt foci show promise as risk markers and intermediate endpoints.
    • Stool-based ras mutation assessment is promising for screening but lacks specificity for prevention studies.
    • Mucosal proliferation presents unclear utility due to discordant epidemiological findings and technical challenges.

    Conclusions:

    • Adenomatous polyps are considered valid endpoints in colorectal cancer research.
    • Aberrant crypt foci and ras mutations are promising biomarkers for risk assessment and chemoprevention.
    • Mucosal proliferation requires further validation and standardization for reliable use in studies.